Pain is a common and debilitating symptom of human immunodeficiency virus (HIV) disease, although it is often underestimated and undertreated, especially in HIV-infected intravenous drug users. It is more likely to occur in the later stages of the HIV disease, where it assumes particular significance, especially in terminally ill patients. However, its successful management is possible, though the goal of effective therapy is hampered by the side effects of highly active antiretroviral therapy and drug–drug interactions. In order to appraise these issues, a search in MEDLINE database was conducted. Book reviews and a search on relevant Web sites were also included. Treatment of HIV is itself very complex and becomes even more difficult when palliative therapy is added. Protease inhibitors, mainly ritonavir, and nonnucleoside reverse transcriptase inhibitors have higher interaction potential, due to their inducer or inhibitory actions on cytochrome P450, posing a risk when coadministered with palliative treatments; so, better outcomes can be achieved with knowledge of pharmacological aspects.
Joint United Nations Programme on HIV/AIDS –UNAIDS. Epidemic Update. In: UNAIDS report on the global AIDS epidemic 2010. WHO Library Cataloguing-in-Publication; 2010:18–61(chap 2). http://www.unaids.org/documents/20101123_GlobalReport_em.pdf. Accessed May 5, 2011.
2.
EasterbrookPMeadwayJ. The changing epidemiology of HIV infection: new challenges for HIV palliative care. J R Soc Med. 2011;94(9):442–448.
WoodCGWhittetSBradbeerCS.ABC of palliative care. HIV infection and AIDS. BMJ. 1997;315(7120):1433–1436.
5.
SelwynPARivardM. Palliative care for AIDS: challenges and opportunities in the era of higly active anti-retroviral therapy. J Palliat Med. 2003;6(3):475–487.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of Antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services; 2011:1–184. http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf. Accessed April 20, 2011.
8.
BreitbartWRosenfeldBPassikSD. Pain in ambulatory AIDS patients I: pain characteristics and medical correlates. Pain. 1996;68(2-3):315–321.
9.
KellMEWalleyJD. Palliative care for HIV en the era of antiretroviral therapy availability: perspectives of nurses in Lesotho. BMC Palliat Care. 2009;8:11.
10.
FrichLMBorgbjergM. Pain and pain treatment in AIDS patients: a longitudinal study. J Pain Symptom Manage. 2000;19(5):339–347.
11.
LarueFFontaineAColleauSM. Underestimation and undertreatment of pain in HIV disease: multicentre study. BMJ. 1997;314(7073):23–28.
12.
NorvalDA. Symptoms and sites of pain experienced by AIDS patients. S Afr Med J. 2004;94(6):450–454.
13.
BrechtlJBreibartWGaliettaMAKrivoSRosenfeldB. The use of highly antiretroviral therapy (HAART) in patients with advanced hiv infection: impact on medical, palliative care, and quality of life outcomes. J Pain Symptom Manage. 2001;21(1):41–51.
14.
NewshanGBennettJHolmanS. Pain and other symptoms in ambulatory HIV patients in the age of highly active antiretroviral therapy. J Assoc Nurses AIDS Care. 2002;13(4):78–83.
15.
BasuSDouglasBDeclanBTAlticeF. Pharmacological pain control for human immunodeficiency virus – infected adults with a history of drug dependence. J Subst Abuse Treat. 2007;32(4):399–409.
16.
TsaoJDobalianANaliboffB. Panic disorder and pain in a national sample of persons living with HIV. Pain. 2004;109(1-2):172–180.
SimmsVMHigginsonIJHardingR. What palliative care-related problems do patients experience at hiv diagnosis? A systematic review of the evidence. J Pain Symptom Manage. 2011;42(5):734–753.
19.
MossV. Palliative care in advanced HIV disease: presentation, problems and palliation. AIDS. 1990;4(suppl 1):S235–S242.
20.
KelleherPCoxSMcKeoghM. HIV infection: the spectrum of symptoms and disease in male and female patients attending a London hospice. Palliat Med. 1997;11(2):152–158.
21.
FantoniMRicciFBorgoC. Multicentre study on the prevalence of symptoms and symptomatic treatment in HIV infection. Central Italy PRESINT Group. J Palliat Care. 1997;13(2):9–13.
22.
La RueFBrasseurLMusseault P. Pain and symptoms in HIV disease: a national survey in France. Abstract: Third Congress of the European Association for Palliative Care. J Palliat Care. 1994;10:95.
SwicaYBreibartW. Treating pain in patients with AIDS and a history of substance abuse. West J Med. 2002;176(1):33–39.
25.
MartinCPehrssonPOOsterbergASonnerborgAHanssonP. Pain in ambulatory HIV-infected patients with or without intravenous drug use. Eur J Pain. 1999;3(2):157–164.
26.
TsaoJSteinJDobalianA. Pain, problem drug use history, and aberrant analgesic use behaviors in persons living with HIV. Pain. 2007;133(1-3):128–137.
27.
ClarkD.“Total pain”, disciplinary power and the body in the work of Cicely Saunders, 1958- 1967. Soc Sci med. 1999;49(6):727–736.
HardingREastrbrookPRaveisVHHigginsonIJMarconiK. Does palliative care improve outcomes for patients with HIV/ AIDS? A systematic review of the evidence. Sex Transm Infect. 2005;81(1):5–14.
LeppertW. Pain management in patients with cancer: focus on opioid analgesics. Curr Pain Headache Rep. 2011;15(4):271–279.
33.
BarbosaANetoI. Manual de Cuidados Paliativos. 1st ed. Lisboa: Núcleo de Cuidados Paliativos - Centro de Bioética - Faculdade de Medicina de Lisboa; 2006.
34.
SerpellM. Pharmacological treatment of chronic pain. Anaesth Intens Care Med. 2005;6(2):39–42.
35.
SaartoTWiffenPJ.Antidepressants for treating neurophatic pain. Cochrane Database Syst Rev. 2007;4:CD005454.
36.
OgbuokiriJE.Pharmacologic Interactions of clinic relevance. In: ÓNeillJSelwynASchietingerH, eds. A Clinical Guide to Supportive and Palliative Care for HIV/AIDS; 2003:549–586 (chap 27). http://hab.hrsa.gov/deliverhivaidscare/files/palliativecare2003.pdf. Accessed February 12, 2010.
37.
PalDKwatraDMinochaMPaturiDBuddaBMitraAK. Efflux transporters- and cytochrome P-450- mediated interactions between drugs of abuse antiretrovirals. Life Sci. 2011;88(21-22):959–971.
38.
BruceRDAlticeFGourevitchMNFriedlandGH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr. 2006;41(5):563–572.
39.
GruberVAMcCance-KatzEF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep. 2010;7(3):152–160.
40.
WynnMDCozzaKLZaporMJWortmannGWArmstrongSC. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics. 2005;46(1):79–87.
KatzEF. Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women. Life Sci. 2011;88:953–958.
43.
BruceRDMcCance-KatzEKharaschEDMoodyDEMorseGD.Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis. 2006;43(suppl 4):S216–S223.
